Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Technology Stocks : Sono-Tek (SOTK) - Profitable Nanotech Co. -- Ignore unavailable to you. Want to Upgrade?

To: Will Lyons who wrote (364)	1/16/2007 3:46:30 PM
From: RikRichter	Respond to of 433

Here is the BSX news: Boston Scientific (BSX): Study favors Taxus over certain other stents SAN FRANCISCO (MarketWatch) -- Boston Scientific Corp. (BSX : Boston Scientific Corporation 3:24pm 01/16/2007 BSX on Friday said an independent study showed that its Taxus paclitaxel-eluting stent exhibited a lower re-intervention rate and equal or lower instances of death or heart attack than the Cypher sirolimus-eluting stent and bare-metal stents. The results of the study were published in the Jan. 1 edition of the European Heart Journal. "We are pleased that this real-world study reconfirms the strong safety and efficacy profile of paclitaxel-eluting stent systems we have seen across our broad range of clinical trials as well as in the millions of Taxus stent systems implanted to date," said Hank Kucheman, group president of the company's interventional cardiology business, in a statement.